Aldendail Carolyn F, Chen Pinyu, Dibble Hannah S, Baute Penry Vanessa
Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC.
Integr Med (Encinitas). 2024 Jul;23(3):32-39.
The debilitating, chronic symptoms of neuropathic pain result in decreased quality of life, depressed mood, and anxiety in patients suffering from neuropathic pain. Despite hundreds of dollars in monthly treatment-related costs, more than half of the patients report inadequate pain relief. Traditional first-line agents are expensive and may have disruptive side effects. Given the disease burden of neuropathic pain, many patients turn to over-the-counter supplements. Here we review two supplements, alpha-lipoic acid (ALA), also known as thioctic acid, and acetyl-L-carnitine (ALC), and data of treatment outcomes from the available literature suggest comparable efficacy to currently available pharmaceuticals for the treatment of neuropathic pain. Meta-analysis of randomized controlled trials demonstrates that ALA can significantly improve neuropathic pain and nerve conduction velocity. ALA has been evaluated in the treatment of multiple sources of neuropathic pain, including chemotherapy-induced peripheral neuropathy, entrapment neuropathies, radicular nerve pain, and burning mouth syndrome. Common dose-dependent side effects include nausea, vomiting, and vertigo. Cost analysis from June 2022 indicates that a clinically effective dose (600 mg/day) of ALA costs patients $14.40 monthly. Two randomized control trials demonstrate that ALC exhibits neuroprotective effects, can regenerate nerves, and improve vibratory perception in the early stages of DPN. In terms of adverse reactions, no significant differences were observed between treatment and placebo groups, implying that ALC is generally well-tolerated. Cost analysis from June 2022 indicates that a clinically effective dose of ALC (2000 mg/day) costs patients $27.60 monthly. Comparable efficacy in clinical trials, minimal side effects, and lower monthly costs suggest that ALA and ALC should be considered among the accepted first-line treatment options for neuropathic pain.
神经性疼痛的慢性症状令人虚弱,会导致患者生活质量下降、情绪低落和焦虑。尽管每月的治疗相关费用高达数百美元,但仍有超过一半的患者表示疼痛缓解不足。传统的一线药物价格昂贵,且可能有不良副作用。鉴于神经性疼痛的疾病负担,许多患者转向非处方补充剂。在此,我们回顾两种补充剂,α-硫辛酸(ALA),也称为硫辛酸,以及乙酰-L-肉碱(ALC),现有文献中的治疗结果数据表明,它们在治疗神经性疼痛方面的疗效与目前可用的药物相当。对随机对照试验的荟萃分析表明,ALA可以显著改善神经性疼痛和神经传导速度。ALA已被评估用于治疗多种神经性疼痛,包括化疗引起的周围神经病变、卡压性神经病变、神经根性神经痛和灼口综合征。常见的剂量依赖性副作用包括恶心、呕吐和眩晕。2022年6月的成本分析表明,ALA的临床有效剂量(600毫克/天)每月花费患者14.40美元。两项随机对照试验表明,ALC具有神经保护作用,可以使神经再生,并改善糖尿病性周围神经病早期的振动觉。在不良反应方面,治疗组和安慰剂组之间未观察到显著差异,这意味着ALC通常耐受性良好。2022年6月的成本分析表明,ALC的临床有效剂量(2000毫克/天)每月花费患者27.60美元。临床试验中相当的疗效、最小的副作用和较低的每月成本表明,ALA和ALC应被视为神经性疼痛公认的一线治疗选择。